A diabetes management application from San Diego-based Tandem Diabetes Care Inc. has received clearance from the U.S. Food and Drug Administration.
The “t:connect” diabetes care software allows patients and their physicians to digitally access data from the company’s “t:slim” insulin pumps and blood glucose meters. The company said that patients can use the software to identify meaningful information and patterns, which allow them to fine-tune therapy and lifestyle choices for improved diabetes management. The program will be available in March.
The company’s “t:slim” insulin pump was in development for about five years before being released last fall. It has the look and feel of a smartphone.
“The software was designed for speed and simplicity to encourage users to upload and review their data more frequently, and to improve the efficiency and productivity of visits with health care providers,” said Kim Blickenstaff, president and CEO of Tandem, in a statement.
Tandem was founded in 2006, and has been funded by several rounds of private financing — most recently $36.4 million in September.
— Meghana Keshavan